Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Human, Monkey, Mouse, Rat, Bovine, Dog, Hamster, Horse, Pig, Rabbit, Sheep (tested or 100% immunogen sequence identity)
IHC - Paraffin (3.75 µg/ml)
Western blot (0.5 - 1.5 µg/ml)
Specificity and Use
THRA / THR Alpha antibody was raised against synthetic peptide C-KEEMIRSLQQRP from an internal region of human THRA (NP_955366.1; NP_003241.2). Percent identity by BLAST analysis: Human, Gorilla, Gibbon, Monkey, Mouse, Rat, Sheep, Hamster, Elephant, Panda, Dog, Bovine, Rabbit, Horse, Pig, Opossum (100%); Chicken, Xenopus, Frog (83%).
LS-E26425 - Lyophilized - 100 µg - $145.00
Immunizing peptide used to generate LS-B4351. Useful for pre-absorption and neutralization of the antibody's antigen binding site.
Human THRA. This antibody is expected to recognize both reported isoforms (NP_955366.1; NP_003241.2). This antibody is not expected to cross-react to THRB.
Thyroid hormone receptor alpha (TR alpha), a NR1 Thyroid Hormone-Like Receptor, mediates the diverse actions of thyroid hormone in development, differentiation, and metabolism. Four protein isoforms are encoded by the same TR alpha genomic locus: TR alpha1 (410 aa) (Nakai et al. 1988), TR alpha2 (490 aa) ( Nakai et al. 1988), TR deltaalpha1 (~154 aa), and TR deltaalpha2 (~237 aa); however, only TR alpha1 is able to bind the ligand ( Lazar et al. 1988).